InVivium Capital β Full Portfolio
9 tracked investments Β· listed companies and verified rows first
Alto Neuroscience is a clinical-stage biopharmaceutical company developing biology-driven medicines for neuropsychiatric conditions, using measurements of brain biology to predict clinical response and identify patients likely to benefit from its drug candidates.
BiotechDigital HealthMental HealthMountain View, US
Amit Etkin(Founder)inAdam Savitz(Executive Officer)Nicholas C. Smith(Executive Officer)Michael Hanley(Executive Officer)Aaron Weaver(Director)Po Yu (Jeff) Chen(Director)
Board seatMichael LiangΒ· per SEC Form D
Co-investorsAble PartnersAlpha Wave GlobalK2 HealthVenturesKorify CapitalVivo CapitalWhat If Ventures+2 more
Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.
BiotechHealthtech
Lyn Baranowski(CEO)in
Co-investorsAndera PartnersCatalio Capital Management, LPF-Prime CapitalNorwest Venture PartnersRiverVest Venture PartnersSR One Capital Management+7 more
San Mateo, US
Board seatAmy Len KobeΒ· per SEC Form D Β· $50M raise Β· filed Nov 2021
Co-investorsAction Potential Venture Capital Ltd.
Co-investorsAccess Venture PartnersAdit Ventures Management, LlcAgilitas Private EquityAlba Infra PartnersALIVE Israel HealthTech FundAlkemi Growth Capital+73 more
Grove Biopharma develops Bionic Biologics, a synthetic drug modality that combines biologic and synthetic design to create cell-permeable molecules targeting intracellular protein-protein interactions.
BiotechDeep TechChicago, US
Geoffrey Duyk(CEO)
Co-investorsDCVC (Data Collective)DCVC BioPortal Innovations
Hinge Bio is a biotechnology company developing next-generation therapeutics based on its GEM-DIMER platform, aimed at improving efficacy and reducing resistance and side effects.
BiotechHealthtechBurlingame, US
Daniel J. Capon(Director)Carin M. Rollins(Executive Officer, Director)Carin Mueller Rollins(Co-Founder & Chief Operating Officer)Harold E. Selick, PhD(Executive Officer, Director)Miriam Siekevitz(Executive Officer)Harold E. "Barry" Selick(Chief Executive Officer & Director)
Co-investorsPoint72Baruch Future VenturesAgent CapitalRidgeback Capital
Onchilles Pharma is a biopharmaceutical company developing novel therapeutics based on scientific research to address unmet medical needs.
BiotechSan Diego, US
Lev Becker, Ph.D.(Director)Marc Nasoff(Chief Development Officer)Court Turner(Executive Officer, Director)Kevin Li, Ph.D.(Director)
A biotechnology company developing a next generation, fully recombinant botulinum toxin.
Virtual Incision develops a miniaturized robotic-assisted surgery (miniRAS) system called MIRA, designed to fit within hospitals' existing infrastructure.
BiotechHealthtechMedical DevicesRoboticsLincoln, US
Dmitry Oleynikov(Director)Shane Farritor(Executive Officer, Director)John P. Murphy(Executive Officer, Director)Mukund Srinivasan(Executive Officer)
BoardTom Shehab(Director)Fred Robertson(Director)
Co-investorsArboretum VenturesInvest NebraskaBaird CapitalEndeavour VisionPrairieGold Venture Partners
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.